These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 8648761)
41. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289 [TBL] [Abstract][Full Text] [Related]
42. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367 [TBL] [Abstract][Full Text] [Related]
43. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. Raviprakash K; Wang D; Ewing D; Holman DH; Block K; Woraratanadharm J; Chen L; Hayes C; Dong JY; Porter K J Virol; 2008 Jul; 82(14):6927-34. PubMed ID: 18480438 [TBL] [Abstract][Full Text] [Related]
44. Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen. Zhang ZS; Weng YW; Huang HL; Zhang JM; Yan YS Mol Med Rep; 2015 Feb; 11(2):1009-16. PubMed ID: 25371092 [TBL] [Abstract][Full Text] [Related]
45. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. Bray M; Men R; Tokimatsu I; Lai CJ J Virol; 1998 Feb; 72(2):1647-51. PubMed ID: 9445071 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037 [TBL] [Abstract][Full Text] [Related]
47. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. Men R; Bray M; Clark D; Chanock RM; Lai CJ J Virol; 1996 Jun; 70(6):3930-7. PubMed ID: 8648730 [TBL] [Abstract][Full Text] [Related]
48. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289 [TBL] [Abstract][Full Text] [Related]
50. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114 [TBL] [Abstract][Full Text] [Related]